Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bennett Levitan

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Pain Medicine (Malden, Mass.)|July 30, 2013
Pain qualities and satisfaction with therapy: a survey of subjects with neuropathic painM Soledad Cepeda, Marsha Wilcox, Bennett Levitan
Therapeutic Innovation & Regulatory Science|September 21, 2018
Structured Approaches to Benefit-Risk Assessment: A Case Study and the Patient PerspectiveBennett Levitan, Lawrence D Phillips, Stuart Walker
Therapeutic Innovation & Regulatory Science|October 8, 2021
U.S. Food and Drug Administration's Patient-Focused Drug Development Initiative: Experience with Integration of Patient-Experience Data in a New Drug Application for Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant for Treatment-Resistant DepressionEva G Katz, Pauline McNulty, Bennett Levitan, et al.
International Clinical Psychopharmacology|July 20, 2016
Benefit-risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophreniaBennett Levitan, Michael Markowitz, Ibrahim Turkoz, et al.
Annals of General Psychiatry|July 13, 2013
Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studiesMichael Markowitz, Dong-Jing Fu, Bennett Levitan, et al.
Journal of Pain Research|March 6, 2013
Trajectories of health care service utilization and differences in patient characteristics among adults with specific chronic pain: analysis of health plan member claimsCharles Ruetsch, Joseph Tkacz, Peter G Kardel, et al.
Clinical Pharmacology and Therapeutics|August 30, 2020
Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant DepressionEva G Katz, David Hough, Teodora Doherty, et al.
Current Medical Research and Opinion|May 16, 2014
Relative importance of benefits and risks associated with antithrombotic therapies for acute coronary syndrome: patient and physician perspectivesZhong Yuan, Bennett Levitan, Paul Burton, et al.
Pharmacoepidemiology and Drug Safety|January 31, 2025
Quantitative Benefit-Risk Assessment of Vaccination Against COVID-19: A Systematic ReviewE Claire Newbern, Lea Wildisen, Rita Verstraeten, et al.
Vaccine|August 10, 2023
Benefit-risk assessment of vaccinesSonali Kochhar, Hector S Izurieta, Rebecca E Chandler, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Pain Medicine (Malden, Mass.)|July 30, 2013
Pain qualities and satisfaction with therapy: a survey of subjects with neuropathic painM Soledad Cepeda, Marsha Wilcox, Bennett Levitan
Therapeutic Innovation & Regulatory Science|September 21, 2018
Structured Approaches to Benefit-Risk Assessment: A Case Study and the Patient PerspectiveBennett Levitan, Lawrence D Phillips, Stuart Walker
Therapeutic Innovation & Regulatory Science|October 8, 2021
U.S. Food and Drug Administration's Patient-Focused Drug Development Initiative: Experience with Integration of Patient-Experience Data in a New Drug Application for Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant for Treatment-Resistant DepressionEva G Katz, Pauline McNulty, Bennett Levitan, et al.
International Clinical Psychopharmacology|July 20, 2016
Benefit-risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophreniaBennett Levitan, Michael Markowitz, Ibrahim Turkoz, et al.
Annals of General Psychiatry|July 13, 2013
Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studiesMichael Markowitz, Dong-Jing Fu, Bennett Levitan, et al.
Journal of Pain Research|March 6, 2013
Trajectories of health care service utilization and differences in patient characteristics among adults with specific chronic pain: analysis of health plan member claimsCharles Ruetsch, Joseph Tkacz, Peter G Kardel, et al.
Clinical Pharmacology and Therapeutics|August 30, 2020
Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant DepressionEva G Katz, David Hough, Teodora Doherty, et al.
Current Medical Research and Opinion|May 16, 2014
Relative importance of benefits and risks associated with antithrombotic therapies for acute coronary syndrome: patient and physician perspectivesZhong Yuan, Bennett Levitan, Paul Burton, et al.
Pharmacoepidemiology and Drug Safety|January 31, 2025
Quantitative Benefit-Risk Assessment of Vaccination Against COVID-19: A Systematic ReviewE Claire Newbern, Lea Wildisen, Rita Verstraeten, et al.
Vaccine|August 10, 2023
Benefit-risk assessment of vaccinesSonali Kochhar, Hector S Izurieta, Rebecca E Chandler, et al.
Pageof 6